AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

AbbVie Inc.NYSE: ABBV

Revenue · Q3 FY2026 · quarter ended Sep 2026

Revenue grows in line with its trailing trend

Q3 FY2026 revenue of $17.4B rose 10.3% year over year, in line with the +10.7% change in trailing-twelve-month revenue. Sequentially, it rose 2.4% from the prior quarter. Over 3 fiscal years it compounded at +1.8% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 19 analysts of $67.73B (+10.7%) for the fiscal year ending Dec 2026, a step up from the +8.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$17.4B+2.4% QoQ
Last fiscal yearDec 2025
$61.16B+8.6% YoY
LTMSep 2026
$66.01B+10.7% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.3%+10.4%+0.1 pp
1 year+8.6%+10.7%+2.2 pp
3-year CAGR+1.8%+9.2%+7.5 pp
5-year CAGR+7.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
61.16B USD
Year-over-year change
+8.6%
4-year CAGR
+2.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ABBV compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +10.7% is the 2nd highest of 10, against a peer median of +5.0%.
  • Over three fiscal years its annual growth of +1.8% compares with a peer median of +5.6%.
ABBV Competitors
Revenue for ABBV and competitors
Company Period LTM YoY 3-year CAGR
JNJJohnson & JohnsonLTM Sep 2026$99.34B USD+7.8%+5.6%
LLYEli Lilly and CompanyLTM Jun 2026$79.67B USD+49.6%+31.7%
MRKMerck & Co., Inc.LTM Jun 2026$66.4B USD+4.2%+3.1%
ABBVAbbVie Inc.LTM Sep 2026$66.01B USD+10.7%+1.8%
PFEPfizer Inc.LTM Jun 2026$63.7B USD-0.2%-14.8%
AZNAstraZeneca PLCLTM Sep 2026$62.17B USD+7.0%+9.8%
NVSNovartis AGLTM Jun 2026$55.63B USD+0.8%+8.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$49.19B USD+3.1%+1.4%
AMGNAmgen Inc.LTM Jun 2026$38.13B USD+9.2%+11.8%
GSKGSK plcLTM Jun 2026£33.2B GBP+5.0%+3.7%
Peer median (excluding ABBV) —+5.0%+5.6%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.2B58.05B54.32B56.33B61.16B
Cost of Revenue17.45B17.41B20.42B16.9B18.2B
Gross Profit38.75B40.64B33.9B39.43B42.96B
Gross Margin69.0%70.0%62.4%70.0%70.2%
Research & Development8.05B6.51B7.68B12.79B9.1B
Selling, General & Admin12.35B15.26B12.87B14.75B14.01B
Operating Expenses20.83B22.52B21.15B30.29B22.87B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
EBITDA23.93B24.17B17.17B14.91B17.63B
EBITDA Margin42.6%41.6%31.6%26.5%28.8%
Operating Income17.92B18.12B12.76B9.14B20.09B
Operating Margin31.9%31.2%23.5%16.2%32.8%
Interest Income39M186M540M648M266M
Interest Expense2.42B2.23B2.22B2.81B2.89B
Other Income / Expenses(4.94B)(4.64B)(6.51B)(5.42B)(13.49B)
Income Before Tax12.99B13.48B6.25B3.72B6.6B
Pre-Tax Margin23.1%23.2%11.5%6.6%10.8%
Income Tax Expense1.44B1.63B1.38B(570M)2.36B
Net Income11.54B11.84B4.86B4.28B4.23B
Net Margin20.5%20.4%9.0%7.6%6.9%
EPS (Basic)6.486.652.732.402.37
EPS (Diluted)6.456.632.722.392.37
Weighted Avg Shares1.77B1.77B1.77B1.77B1.77B
Weighted Avg Shares (Diluted)1.78B1.78B1.77B1.77B1.77B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.